

# Voting Results

## General Meeting ONWARD Medical N.V. | 11 June 2025

Issued share capital (ISC): 44,645,402

Shares represented at the meeting: 20,582,173 (being 46.1% of the ISC)



	Agenda Item	Number of votes validly voted on	% of ISC	Votes FOR	Votes ABSTAIN	Votes AGAINST	Resolution adopted with a majority of
3	Adoption of the annual accounts over the financial year 2024	20,582,173	46.1%	20,578,373	3,800	-	<b>99.9%</b>
4	Implementation of the compensation policy over the financial year 2024 (advisory non-binding voting item)	20,582,173	46.1%	16,682,491	74,912	3,824,770	<b>81.1%</b>
5	Approval of the compensation policy for the board	20,582,173	46.1%	16,676,641	80,762	3,824,770	<b>81.0%</b>
7	Release of the directors from liability for the exercise of their duties during the financial year 2024	20,582,173	46.1%	19,012,201	8,670	1,561,302	<b>92.4%</b>
8	Appointment of Ernst & Young Accountants LLP for the external audit of the Company's annual accounts for the financial year 2025	20,582,173	46.1%	20,579,143	2,800	230	<b>99.9%</b>
9	Re-appointment Mr. David Lawrence Marver as executive director	20,582,173	46.1%	20,508,459	73,132	582	<b>99.6%</b>
10	Re-appointment Mr. Ian Curtis as non-executive director	20,582,173	46.1%	20,107,071	3,170	471,932	<b>97.7%</b>
11	Appointment Ms. Rahma Samow as non-executive director	20,582,173	46.1%	20,508,459	73,632	82	<b>99.6%</b>
12	Appointment Mr. Robert Johannes Wilhelmus ten Hoedt as non-executive director	20,582,173	46.1%	19,688,135	70,282	823,756	<b>95.7%</b>
13	Delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for 10% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection therewith	20,582,173	46.1%	19,574,475	75,932	931,766	<b>95.1%</b>
14	Delegation of the authority of the board to issue ordinary shares and to grant rights to subscribe for ordinary shares in the capital of the Company for an additional 50% of the Company's issued share capital and to limit or exclude pre-emptive rights in connection with a one or more potential capital raises, or for other strategic purposes	20,582,173	46.1%	16,648,675	4,220	3,929,278	<b>80.9%</b>
15	Authorization of the board to acquire ordinary shares in the Company's capital	20,582,173	46.1%	20,501,841	75,432	4,900	<b>99.6%</b>